Discover
etrolizumab (RG7413) / RocheHIBISCUS I: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1) (clinicaltrials.gov) - Mar 30, 2020 - P3; N=358; Completed; Sponsor: Hoffmann-La Roche; Active, not recruiting --> Completed; Trial completion date: Jul 2020 --> Mar 2020
Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&JSimponi self-injection formulation for ulcerative colitis now reimbursed through NHI (Mitsubishi Tanabe Press Release) - Apr 1, 2020
Myoconda (clarithromycin/clofazimine/rifabutin) / RedHillMAPUS2: Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease (clinicaltrials.gov) - Apr 1, 2020 - P3; N=54; Completed; Sponsor: RedHill Biopharma Limited; N=331 --> 54; Trial completion date: Jul 2018 --> Aug 2019
Remicade (infliximab) / Mitsubishi Tanabe, J&JA Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) (clinicaltrials.gov) - Apr 1, 2020 - P4; N=1; Completed; Sponsor: Janssen Scientific Affairs, LLC; Recruiting --> Completed; N=40 --> 1
